| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| CLEC4C | HOT CLC-H5245 | Human CLEC4C / BDCA2 Protein, His Tag | Human | HEK293 | ![]() | SDS-PAGE | $415.00 100ug | ||
| CLEC4C | Cynomolgus CLEC4C / BDCA2 Protein, Fc Tag (MALS verified) | Cynomolgus | HEK293 | ![]() | MALSSDS-PAGE | $360.00 100ug | |||
| CLEC4C | Cynomolgus CLEC4C / BDCA2 Protein, His Tag (MALS verified) | Cynomolgus | HEK293 | ![]() | MALSSDS-PAGE | $360.00 100ug | |||
| CLEC4C | Avitag CLC-C82Q3 | Biotinylated Cynomolgus CLEC4C / BDCA2 Protein, Avitag™,His Tag | Cynomolgus | HEK293 | ![]() | SDS-PAGE | $360.00 25ug | ||
| CLEC4C | Human CLEC4C / BDCA2 Protein, Fc Tag | Human | HEK293 | ![]() | SDS-PAGE | $360.00 100ug | |||
| CLEC4C | Avitag CLC-H82Q3 | Biotinylated Human CLEC4C / BDCA2 Protein, Avitag™,His Tag | Human | HEK293 | ![]() | SDS-PAGE | $360.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Litifilimab | BIIB-059 | Phase 3 Clinical | Biogen Inc | Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic | Details |
| SSGJ-626 | SSGJ-626; 626 | Phase 2 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic | Details |
| DB-2304 | DB-2304 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Autoimmune Diseases; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic | Details |
| ANB-101 | CBS-004; ANB101 | Phase 1 Clinical | Capella Bioscience Ltd | Inflammation; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Scleroderma, Systemic | Details |
| BCD-256 | BCD-256 | Phase 1 Clinical | BIOCAD JSC | Lupus Erythematosus, Systemic | Details |
| GB-19 | GB-19; GB19 | Phase 1 Clinical | Shandong Kexing Bio-Products Co Ltd | Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic | Details |
| Recombinant anti-BDCA2 humanized monoclonal antibody (Sansheng Guojian) | Phase 1 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic | Details | |
| HC-022 | HC-022; HC022 | Phase 1 Clinical | Shanghai Hongcheng Pharmaceutical Co Ltd | Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic | Details |
| LBL-047 | DNTH-212; LBL-047; DNTH212 | Phase 1 Clinical | Nanjing Leadsbiolabs Co Ltd | Autoimmune Diseases; Lupus Erythematosus, Systemic | Details |